title: Topics in lipoprotein glomerulopathy: an overview.
abstract: Here, we introduce four topics in lipoprotein glomerulopathy (LPG). To date, approximately 150 cases of LPG have been reported worldwide. Recently two groups studied hot spots of APOE-Sendai and APOE-Kyoto, the representative variants of LPG, in narrow areas of Japan and China, respectively. They suggest that both variants have descended through a founder effect. APOE-Sendai and APOE-Kyoto cause different transformations of apolipoproteins aggregating lipoproteins and resulting in lipoprotein thrombi within the glomerulus. Moreover, the macrophage impairment in LPG may provide another mechanism for lipoprotein thrombi in which massive lipoproteins accumulate in the glomerulus without foam cells. On the other hand, the administration of fibrate with the intensive control of triglyceride and apolipoprotein E particularly from the early phase will ameliorate LPG and prevent renal dysfunction.
authors.affiliation: General Medical Research Center, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan, tsaito@fukuoka-u.ac.jp.
authors.forename: Takao
authors.initials: T
authors.lastname: Saito
authors.forename: Akira
authors.initials: A
authors.lastname: Matsunaga
authors.forename: Kenji
authors.initials: K
authors.lastname: Ito
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakashima
mesh_terms: D053329:Apolipoprotein E2 / Q000235:genetics; D001057:Apolipoproteins E / Q000097:blood / Q000235:genetics; D011345:Fenofibrate / Q000627:therapeutic use; D018703:Founder Effect; D006801:Humans; D015228:Hypertriglyceridemia / Q000517:prevention & control; D007674:Kidney Diseases / Q000188:drug therapy* / Q000473:pathology; D007678:Kidney Glomerulus / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D009404:Nephrotic Syndrome / Q000517:prevention & control; D051436:Renal Insufficiency, Chronic / Q000517:prevention & control
chemical_list: D053329:Apolipoprotein E2; D001057:Apolipoproteins E; C504713:apolipoprotein E2 (Kyoto); D011345:Fenofibrate